Please provide your email address to receive an email when new articles are posted on . Simlandi (adalimumab-ryvk) hit the market as first interchangeable, citrate-free Humira biosimilar in a ...

Please provide your email address to receive an email when new articles are posted on . Quallent will offer both low- and high-concentration citrate-free adalimumab-adbm. The existing biosimilar ...

SIMLANDI is the first high-concentration, citrate-free biosimilar to Humira that has been granted an interchangeability status by the FDA, and will qualify for interchangeable exclusivity for the 40mg ...

Alvotech and Teva have received permission from the Food and Drug Administration for Simlandi (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult ...

REYKJAVIK, Iceland and PARSIPPANY, N.J. and TEL AVIV, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- Alvotech, a global biotech company specializing in the development and manufacture of biosimilar ...

Boehringer Ingelheim and GoodRx are launching a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), at a low cash price available ...

RIDGEFIELD, Conn., May 1, 2024 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of ...

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical ...

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership ...